o2h-ventures

Exonate aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies.

Transforming the lives of those suffering from vision loss
A revolutionary eye drop
Eye drops to treat diseases such as wet AMD and DME which will not onlyoffer improved quality of life for patients
Status Active
Website https://www.exonate.com/
Category Biotech
Modality Small Molecule
Therapautics Area Ocular
Headquaters Cambridge, UK
Partner Johnson and Johnson
Investment Portfolio Fund Investment
Co-Investors The University Of Nottingham Parkwalk, Angel Cofund, Wren Capital University of Bristol Enterprise Fund